AI-linked hiring in CDMO industry jumps nearly 3‑fold in two years

#

Hiring for AI‑linked roles in India's CDMO sector has surged dramatically, nearly tripling over the past two years. The Economic Times reports that demand for artificial‑intelligence expertise will almost triple between 2023 and 2025, signalling a rapid shift toward automation and advanced analytics in drug development and manufacturing. The trend is concentrated in manufacturing and operations, but a talent gap is already emerging, especially for high‑value positions.

What happened

The report released by the Economic Times highlights a sharp rise in AI‑linked hiring across contract development and manufacturing organisations (CDMOs). Between 2023 and 2025, the sector expects demand for AI skills to increase by almost three‑fold. Companies are adding data scientists, machine‑learning engineers, and automation specialists to teams that traditionally focused on chemistry, process engineering, and quality control. The surge reflects a broader move to embed AI into formulation design, process optimization, and predictive maintenance. While the exact numbers are not disclosed, the phrasing "nearly 3‑fold" suggests a 200‑plus percent jump in advertised positions. The report notes that manufacturing and operations remain the primary domains where AI talent is being absorbed, underscoring the sector's focus on efficiency and scale.

Why it matters

The rapid expansion of AI‑linked hiring matters for several reasons. First, it signals that CDMOs are no longer peripheral service providers; they are becoming technology‑driven partners in the pharmaceutical pipeline. By leveraging AI, firms can shorten development cycles, reduce batch failures, and improve cost predictability. Second, the talent gap highlighted in the report could constrain growth if companies cannot fill high‑value roles quickly enough. Shortages of skilled AI professionals may force CDMOs to compete fiercely for talent, driving up salaries and potentially shifting recruitment toward overseas markets. Finally, the trend may reshape the competitive landscape, rewarding firms that successfully integrate AI with faster time‑to‑market and higher quality outputs.

The bigger picture

India's CDMO industry has long been a growth engine for the country's pharmaceutical exports, accounting for a sizable share of global contract manufacturing capacity. Over the past decade, the sector has benefited from government incentives, a skilled engineering workforce, and a robust domestic drug market. The current AI hiring surge aligns with global patterns where life‑science firms are embedding machine learning into R&D and manufacturing. In the United States and Europe, similar moves have been recorded, with AI‑enabled platforms accelerating clinical trial design and supply‑chain resilience. Within India, the rise of AI talent mirrors broader national initiatives such as the National AI Strategy, which aims to position the country as a hub for AI research and application. The CDMO sector's pivot to AI therefore reflects both industry‑specific pressures and a wider governmental push toward digital transformation.

What's next

Looking ahead, several developments are likely to shape the trajectory of AI‑linked hiring in CDMOs. Companies are expected to formalize AI roadmaps that outline short‑term pilots and long‑term integration plans. Partnerships with tech firms and academic institutions may become commonplace, providing access to cutting‑edge algorithms and talent pipelines. Regulatory bodies could also influence adoption rates; clearer guidelines on AI‑driven process validation would reduce uncertainty for firms. Meanwhile, the talent gap may prompt CDMOs to invest in upskilling existing staff through internal training programs or certifications. Observers should watch for announcements of large‑scale AI centers of excellence within major CDMOs, as well as any shifts in salary benchmarks for AI roles.

Key takeaways

• AI‑linked hiring in India's CDMO sector is projected to nearly triple between 2023 and 2025.
• Manufacturing and operations are the primary functions absorbing AI talent.
• A talent gap, especially for high‑value AI roles, is emerging and could affect growth.
• The trend mirrors global moves toward AI in pharma and aligns with India's national AI agenda.
• Future developments may include strategic partnerships, regulatory guidance, and intensified upskilling efforts.